The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents

@article{Liu2002TheIV,
  title={The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents},
  author={Wai Man Liu and Lewis A. Stimson and Simon P. Joel},
  journal={British Journal of Cancer},
  year={2002},
  volume={86},
  pages={1472 - 1478}
}
Chronic myeloid leukaemia is typically characterised by the presence of dysregulated BCR–ABL tyrosine kinase activity, which is central to the oncogenic feature of being resistant to a wide range of cytotoxic agents. We have investigated whether the inhibition of this tyrosine kinase by the novel compound STI571 (formerly CGP57148B) would render K562, KU812 cell lines and chronic myeloid leukaemia-progenitor cells sensitive to induction of cell kill. Proliferation assays showed STI571 to be an… CONTINUE READING
BETA

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Similar Papers

Loading similar papers…